Health & Fitness
Health and Fitness
Health and Fitness
Thu, January 27, 2011
Bronstein, Gewirtz & Grossman, LLC Investigating Possible Securities Law Violations at MannKind Corporation
NEW YORK--([ BUSINESS WIRE ])--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of MannKind Corporation (aMNKDa or the aCompanya) (NASDAQ:MNKD), concerning whether the company has violated federal securities laws.
On January 19th, 2011 trading of MNKD shares was halted by Nasdaq Group Inc. because the biotechnology company founded by the billionaire inventor Alfred Mann planned to release news, Nasdaq spokesperson Wayne Lee said. Prior to the trading halt of MNKD shares, the stock dropped 38% to $6.05 that morning on no news and then subsequently shot back up to $9.11 when the trading halt began. Shares of the Company then plunged nearly 50% in after hour trading after the Food and Drug Administration deferred approving Afrezza, an inhaled insulin treatment for hyperglycemia. On this news the company shares plummeted to $5.21.
If you are aware of any facts relating to this investigation, or purchased shares of MNKD, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [ eitan@bgandg.com ]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firma™s expertise includes general corporate work, private securities offerings, and securities arbitration.
